Antimicrobial treatment of lower respiratory tract infections in the hospital setting

Pharmacology, Toxicology and Pharmaceutical Science

• Antiinfective Agent 100%
• Quinolone Derivative 100%
• Lower Respiratory Tract Infection 100%
• Community Acquired Pneumonia 80%
• Hospital Acquired Pneumonia 80%
• Levofloxacin 60%
• Short Course Therapy 40%
• Ventilator Associated Pneumonia 40%
• Ceftriaxone 40%
• Chronic Bronchitis 40%
• Health Care Associated Pneumonia 40%
• Respiratory Tract Infection 40%
• Clinical Trial 20%
• Antibiotics 20%
• Infectious Agent 20%
• Drug Concentration 20%
• Lactam 20%
• Macrolide 20%
• Sultamicillin 20%
• Erythromycin 20%
• Monotherapy 20%
• Moxifloxacin 20%
• Gatifloxacin 20%
• Azithromycin 20%
• Ertapenem 20%
• Gemifloxacin 20%
• Telithromycin 20%
• Multidrug Resistance 20%
• Streptococcus Pneumonia 20%
• Penicillin 20%

Keyphrases

• Antimicrobial Therapy 100%
• Community-acquired Pneumonia 100%
• Lower Respiratory Tract Infection 100%
• Hospital Setting 100%
• Fluoroquinolones 50%
• Levofloxacin 37%
• Hospitalization 37%
• Short-term Treatment 25%
• Ceftriaxone 25%
• Respiratory Infection 25%
• Ventilator-associated Pneumonia 25%
• Healthcare-associated Pneumonia 25%
• Acute Exacerbation of Chronic Bronchitis 25%
• Clinical Trials 12%
• Early Onset 12%
• Monotherapy 12%
• Antibiotics 12%
• High Dose 12%
• Azithromycin 12%
• Multidrug Resistance 12%
• Moxifloxacin 12%
• Resistant Strains 12%
• Streptococcus Pneumoniae 12%
• Gram-positive Pathogens 12%
• Drug Concentration 12%
• Gram-negative 12%
• Erythromycin 12%
• Current Guidelines 12%
• Penicillin Resistance 12%
• Macrolides 12%
• Therapy Regimen 12%
• Gatifloxacin 12%
• Ertapenem 12%
• Gemifloxacin 12%
• Atypical Pathogens 12%
• Respiratory Fluoroquinolones 12%
• Pneumonia Ventilator-associated 12%
• Telithromycin 12%
• Resistance Development 12%
• Beta-lactams 12%
• Ampicillin/sulbactam 12%